Skip to content

China

BeOne Medicines revenue surges 35% in Q1

BeOne Medicines Ltd, a listed global oncology biotech, reported a first-quarter revenue of $1.5 billion for 2026, up 35 percent year-on-year, driven by continued growth of its blood cancer drug, Brukinsa, and expansion into overseas markets. The US-listed Chinese biotech, also listed in Hong Kong and Shanghai, said Brukinsa generated $1.1 billion in global sales…

China’s role in global business strategies highlighted

China will remain important to the long-term strategies of multinational companies, given its unmatched market scale, evolving consumer demand and increasingly strong innovation ecosystem, according to a senior executive. Kati Najipoor-Smith, head of the Global Automotive Practice at Heidrick & Struggles, sees China not only as an important market, but also as an increasingly important…

China approves domestic breast cancer drug for expanded use

China’s top drug regulator approved a domestically developed innovative breast cancer drug for expanded use on Wednesday, offering a new first-line treatment option for patients with a common subtype of advanced breast cancer. The drug, Culmerciclib capsules, was developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical. It has been approved by…

China approves first commercial trial for satellite IoT

The Ministry of Industry and Information Technology said it has approved Beijing Guodian Gaoke Technology Co to launch a two-year commercial pilot program for satellite-based internet of things services, the first such commercial trial in the country. The move marks a significant step in the country’s efforts to advance commercial space applications and foster new…

Walmart’s Chengdu store turns prototype for nationwide upgrades

Customers shop on April 24 at Walmart’s newly opened Chengdu store in Sichuan province, marking the launch of its next-generation store model in China. CHINA DAILY Walmart China’s recently revamped Chengdu, Sichuan province, store marks the launch of its next-generation store model in the country, signaling a rising trend of proximity-focused formats in retail. The…

Shanghai substation powers up Lexus’ EV production plans

A substation dedicated to serving the power supply of Japanese carmaker Toyota’s wholly-owned Lexus electric vehicle plant officially began operations in Shanghai on April 30, paving the way for the plant’s mass production, according to State Grid Shanghai Municipal Electric Power Co. Situated in Shanghai’s Jinshan district, the project involves an investment of 14.6 billion…

Dolby eyes China as key hub for innovation

Leveraging its first global flagship experience center — Dolby House Shanghai — Dolby, a global technology major in audio, imaging and voice, said it will deepen its cooperation with partners in China, as the country has become a key innovation hub for the company, said a senior executive. “Chinese consumers are actually teaching us what’s…

Samsung to cease sale of home appliances on Chinese mainland

Global electronics maker Samsung announced on Wednesday that it is to cease sales of all home appliance products on the Chinese mainland market. The move covers all home appliance categories, including televisions and monitors. Smartphone products will continue to be sold as usual. In a statement published on its official website, the company said the…

Dreame from China amazes Silicon Valley

Chinese tech company Dreame unveils its next-generation robotic lawn mower in Silicon Valley. Powered by LiDAR, SLAM navigation and AI algorithms, the Dreame Roboticmower can identify 300 types of backyard obstacles. Wu Dongxiao, head of Dreame Roboticmower, said the future Dreame Roboticmower will go beyond mowing to handle watering, fertilization and inspection, becoming a truly…

Chinese drugmaker scores big in US insulin market

China’s Sunshine Lake Pharma has won US Food and Drug Administration approval for its insulin glargine injection, marking the first time a Chinese-developed insulin has obtained the regulator’s “interchangeable biosimilar” designation — a milestone that underscores the accelerated entry of Chinese biopharmaceutical companies into high-end global markets. The label allows pharmacists in the United States…